PX-3

PX-3
Legal status
Legal status
Identifiers
  • N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H28N4O2
Molar mass404.514 g·mol−1
3D model (JSmol)
  • NC(=O)[C@H](Cc1ccccc1)NC(=O)c2nn(CC3CCCCC3)c4ccccc24
  • InChI=1S/C24H28N4O2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20H,2,5-6,11-12,15-16H2,(H2,25,29)(H,26,30)/t20-/m0/s1
  • Key:DMHWDSGURMXMGE-FQEVSTJZSA-N

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2][3][4]

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.[5][6]

  1. ^ "APP-CHMINACA". Cayman Chemical. Retrieved 24 June 2015.
  2. ^ WO 2009106980, "Indazole derivatives" 
  3. ^ "EWS Forum - In Belgien wurde die neue psychoaktive Substanz N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide (APP-CHMINACA) identifiziert". Retrieved 24 June 2015.
  4. ^ Presley BC, Logan BK, Jansen-Varnum SA (April 2020). "In Vitro Metabolic Profile Elucidation of Synthetic Cannabinoid APP-CHMINACA (PX-3)". Journal of Analytical Toxicology. 44 (3): 226–236. doi:10.1093/jat/bkz086. PMID 31665324.
  5. ^ "EWS Forum - In Schweden wurde die neue psychoaktive Substanz N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-APP-PICA) identifiziert". Retrieved 24 June 2015.
  6. ^ "EWS Forum - In Schweden wurden folgende drei neue psychoaktive Substanzen identifiziert". Retrieved 24 June 2015.